HK1002936A1 - N-alkyl-2-substituted atp analogues - Google Patents

N-alkyl-2-substituted atp analogues

Info

Publication number
HK1002936A1
HK1002936A1 HK98102001A HK98102001A HK1002936A1 HK 1002936 A1 HK1002936 A1 HK 1002936A1 HK 98102001 A HK98102001 A HK 98102001A HK 98102001 A HK98102001 A HK 98102001A HK 1002936 A1 HK1002936 A1 HK 1002936A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
independently represent
halogen
phenyl
atp analogues
Prior art date
Application number
HK98102001A
Other languages
English (en)
Inventor
Anthony Howard Ingall
Peter Alan Cage
Nicholas David Kindon
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939302636A external-priority patent/GB9302636D0/en
Priority claimed from GB939325712A external-priority patent/GB9325712D0/en
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of HK1002936A1 publication Critical patent/HK1002936A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK98102001A 1993-02-10 1998-03-10 N-alkyl-2-substituted atp analogues HK1002936A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939302636A GB9302636D0 (en) 1993-02-10 1993-02-10 Compounds
GB939325712A GB9325712D0 (en) 1993-12-16 1993-12-16 Compounds
PCT/GB1994/000237 WO1994018216A1 (en) 1993-02-10 1994-02-08 N-alkyl-2-substituted atp analogues

Publications (1)

Publication Number Publication Date
HK1002936A1 true HK1002936A1 (en) 1998-09-25

Family

ID=26302434

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98102001A HK1002936A1 (en) 1993-02-10 1998-03-10 N-alkyl-2-substituted atp analogues

Country Status (26)

Country Link
US (2) US5721219A (xx)
EP (1) EP0683789B1 (xx)
JP (1) JP3083156B2 (xx)
KR (1) KR100315612B1 (xx)
CN (1) CN1042430C (xx)
AT (1) ATE159950T1 (xx)
AU (1) AU679721B2 (xx)
CA (1) CA2155673C (xx)
CZ (1) CZ286050B6 (xx)
DE (1) DE69406649T2 (xx)
DK (1) DK0683789T3 (xx)
ES (1) ES2108425T3 (xx)
FI (1) FI110687B (xx)
GR (1) GR3025995T3 (xx)
HK (1) HK1002936A1 (xx)
HU (1) HU221501B (xx)
IL (1) IL108602A (xx)
NO (1) NO305209B1 (xx)
NZ (1) NZ261159A (xx)
PL (1) PL175623B1 (xx)
RU (1) RU2136693C1 (xx)
SG (1) SG47943A1 (xx)
SK (1) SK281309B6 (xx)
TW (1) TW326045B (xx)
UA (1) UA54366C2 (xx)
WO (1) WO1994018216A1 (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679721B2 (en) * 1993-02-10 1997-07-10 Astrazeneca Ab N-alkyl-2-substituted ATP analogues
EP0929218A4 (en) * 1996-10-30 2001-05-16 Univ North Carolina R2Y RECEPTOR ANTAGONISTS
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
AU2003257524B2 (en) * 1997-07-11 2006-04-06 Astrazeneca Ab New formulation
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6303774B1 (en) 1999-08-20 2001-10-16 Sri International Nucleoside pyrophosphate and triphosphate analogs and related compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
JP2005525358A (ja) * 2002-02-28 2005-08-25 ビオタ インコーポレーティッド ヌクレオチド模倣体およびそのプロドラッグ
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
BR0312778A (pt) * 2002-07-18 2005-05-03 Sankyo Co Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat
AU2003284594B2 (en) * 2002-11-21 2009-01-15 Kowa Co., Ltd Peritoneal dialysis method
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
EA028885B1 (ru) * 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
JP6577165B2 (ja) * 2011-01-26 2019-09-18 北京康倍得医▲藥▼技▲術▼▲開▼▲發▼有限公司 リボフラノシルプリン化合物、その調製方法、およびその使用
WO2012109406A1 (en) 2011-02-09 2012-08-16 The Medicines Company Methods for treating pulmonary hypertension
AU2012290089B2 (en) 2011-08-01 2016-09-29 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
CN106102750A (zh) 2013-03-09 2016-11-09 凯西制药公司 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
CN104447927A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛一水合物晶体及其制备方法
CN104447928A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛二水化合物
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN105273025B (zh) * 2014-07-22 2019-07-26 上海医药工业研究院 一种制备坎格雷洛的中间体及其制备方法和应用
MA41326A (fr) 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN109232694A (zh) * 2015-11-06 2019-01-18 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
CN107973798B (zh) * 2016-10-25 2020-04-24 上海医药工业研究院 2-[(3,3,3-三氟丙基)硫代]-6-氨基-9h-嘌呤及制法
CN107973832B (zh) * 2016-10-25 2021-11-12 上海医药工业研究院 6-n-[2-(甲硫基)乙基]-2-[(3，3，3-三氟丙基)硫代]腺苷的制法
CN106674322B (zh) * 2016-12-07 2019-04-16 上海博志研新药物技术有限公司 一种坎格雷洛中间体的纯化方法
WO2018185715A1 (en) * 2017-04-06 2018-10-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of n6-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene) bisphosphonic acid and its pharmaceutically acceptable salts
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
ES2905104T3 (es) * 2017-11-10 2022-04-07 Olon Spa Método eficiente para la preparación de Cangrelor
CN109912674A (zh) * 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US20190241606A1 (en) * 2018-02-05 2019-08-08 Scinopharm Taiwan, Ltd. Process for preparation of cangrelor tetrasodium and intermediate therefor
CN108033983B (zh) * 2018-02-09 2021-06-08 盐城锦明药业有限公司 一种2‐(3,3,3‐三氟丙基)硫代腺苷的合成方法
EP4289435A1 (en) 2022-06-07 2023-12-13 Université de Liège N-alkyl-2-substituted atp analogues for use as antibacterial agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
EP0464206A4 (en) * 1989-03-24 1992-05-13 Daiichi Pharmaceutical Co., Ltd. Drug for improving brain function
PL297372A1 (en) * 1991-04-06 1993-09-06 Fisons Plc Atp analogs
GB9107236D0 (en) 1991-04-06 1991-05-22 Fisons Plc Compounds
AU679721B2 (en) * 1993-02-10 1997-07-10 Astrazeneca Ab N-alkyl-2-substituted ATP analogues

Also Published As

Publication number Publication date
DE69406649D1 (de) 1997-12-11
IL108602A (en) 1999-12-22
CA2155673C (en) 2004-08-17
HU221501B (en) 2002-10-28
DE69406649T2 (de) 1998-03-05
PL310160A1 (en) 1995-11-27
FI110687B (fi) 2003-03-14
UA54366C2 (uk) 2003-03-17
CN1119869A (zh) 1996-04-03
SG47943A1 (en) 1998-04-17
PL175623B1 (pl) 1999-01-29
NO305209B1 (no) 1999-04-19
US5721219A (en) 1998-02-24
ES2108425T3 (es) 1997-12-16
AU679721B2 (en) 1997-07-10
CN1042430C (zh) 1999-03-10
FI953794A0 (fi) 1995-08-10
NO953126D0 (no) 1995-08-09
AU5977094A (en) 1994-08-29
KR100315612B1 (ko) 2002-06-20
TW326045B (en) 1998-02-01
RU2136693C1 (ru) 1999-09-10
EP0683789B1 (en) 1997-11-05
ATE159950T1 (de) 1997-11-15
CA2155673A1 (en) 1994-08-18
HUT72464A (en) 1996-04-29
IL108602A0 (en) 1994-05-30
JPH08506335A (ja) 1996-07-09
US5955447A (en) 1999-09-21
SK281309B6 (sk) 2001-02-12
JP3083156B2 (ja) 2000-09-04
WO1994018216A1 (en) 1994-08-18
SK99495A3 (en) 1996-02-07
GR3025995T3 (en) 1998-04-30
CZ286050B6 (cs) 1999-12-15
FI953794A (fi) 1995-08-10
EP0683789A1 (en) 1995-11-29
NO953126L (no) 1995-09-28
DK0683789T3 (da) 1998-02-09
CZ203295A3 (en) 1995-12-13
NZ261159A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
PL310160A1 (en) N-alkyl-2-substituted atp analogues
HUP0301690A2 (hu) Szinergikus eljárások és készítmények rák kezelésére
ZA919181B (en) Oxazolopyridine derivatives,processes for preparing these and pharmaceutical compositions containing them
GB9211172D0 (en) Compounds
PL308666A1 (en) Derivatives of 11,21-bisphenyl-19-norpregnan, method of obtaining them and pharmaceutical composition containing such derivatives
ES455741A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
DE69330601D1 (de) Serotoninergische ergolin derivate
HUP0204217A2 (en) Novel a-500359 derivatives
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
HUP0100751A2 (hu) Új aril-vagy heteroaril-kinolinilfoszfonsav-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények
GR3037045T3 (en) Pseudopeptides derived from neurokinines, process of preparation and pharmaceutical compositions comprising them
JO1825B1 (en) Therapeutic agents
MX9708525A (es) Derivados de vinilpirrolidinon-cefalosporina.

Legal Events

Date Code Title Description
PF Patent in force
AS Change of ownership

Owner name: ASTRAZENECA UK LIMITED

Free format text: FORMER OWNER(S): ASTRA PHARMACEUTICALS LIMITED

CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20140207